BeiGene presents interim analysis results of RATIONALE 303 trial of tislelizumab in second- or third-line non-small cell lung cancer at the AACR Annual Meeting .
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest